Cabozantinib is an antineoplastic drug discovered and developed by Exelixis. It comes in two formulations Cometriq® (capsules) and Cabometyx® (tablets) which are not bioequivalent hence not interchangeable. They both contain cabozantinib as their active ingredient, but each contain different subcomponents causing a change in the pharmacokinetics and pharmacodynamics. Cometriq® was approved in 2012 and Cabometyx® in 2017 by the FDA. Some tumors are produced due to the overactivity of receptor and intracellular tyrosine kinases. Cabozantinib is part of the multikinase inhibitor group of drugs which could be better than the use of single kinase inhibitor depending on several factors in certain situations. Multiple clinical studies performed proved the effectivity of cabozantinib compared to placebo or other multikinase inhibitor to be presenting better outcomes in several tumors. Tumors primarily targeted are renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid carcinoma by Cabometyx® and medullary thyroid carcinoma by Cometriq®.